摘要
转移性结直肠癌(mCRC)是一个全球范围内重大的健康问题,仍需要创新的方法来提高治疗效果。通过回顾性分析接受呋喹替尼联合PD-L1抑制剂(靶免组)对比接受呋喹替尼(靶向组)治疗微卫星稳定型(Microsatellite stability,MSS)或错配修复正常型(Effective mismatch repair,pMMR)晚期不可切除转移性结直肠癌(Metastatic colorectal cancer,mCRC)患者的疗效及安全性,探索呋喹替尼联合PD-L1抑制剂治疗晚期结直肠癌的可行性。回顾性收集2019年1月至2022年6月在宁波大学附属李惠利医院获得的晚期MSS/pMMR mCRC患者资料,并分析比较靶免组和靶向组患者的疗效和安全性。对比分析两组患者的客观缓解率(Objective response rate,ORR)、无进展生存期(Progression-free survival,PFS)及不良反应(Adverse events,AEs)。所有数据采用SPSS 25.0软件和GraphPad Prism 8.0进行分析。符合标准的40名患者被分为靶免组(n=19)和靶向组(n=21)。靶免组和靶向组的ORR分别为5.0%和0,DCR分别为68.4%和52.3%。靶免组的mPFS高于靶向组(分别为5.8个月和4.5个月;P=0.0135)。两组患者在不良反应方面差异无统计学意义,3例患者(7.5%)出现与治疗相关的3级不良反应,无治疗相关性死亡。本研究提供了令人信服的证据,支持对mCRC患者进行呋喹替尼和一种PD-L1抑制剂的联合治疗。本研究提示mCRC患者接受PD-L1抑制剂联合呋喹替尼治疗较呋喹替尼单药治疗具有更好的生存获益及可控的毒性反应。
Metastatic colorectal cancer(mCRC)remains a significant global health challenge,necessitating innovative approaches to enhance treatment outcomes.To explore the feasibility of furquintinib combined with an anti-PD-L1 inhibitor in treating mCRC,a retrospective analysis was conducted to compare the efficacy and safety of microsatellite stability(MSS)or proficient mismatch repair(pMMR)mCRC patients who received furquintinib and a PD-L1 inhibitor(the target and immunotherapy group)with those who received only furquintinib(the target group).Data from patients with advanced MSS/pMMR mCRC at the Affiliated Lihuili Hospi-tal,Ningbo University,spanning from January 2019 to June 2022 were gathered.A comprehensive analysis to assess and compare the efficacy and safety of both groups were conducted.Key parameters examined included the objective response rate(ORR),progres-sion-free survival(PFS),and adverse events(AEs).Statistical analysis was performed using SPSS 25.0 software and GraphPad Prism 8.0.The result showed a total of 40 eligible patients were included in this study,with 19 cases in the target and immunotherapy group and 21 cases in the target group.In the target and immunotherapy group,the total remission rate was 5.0%,while the target group showed no instances of remission.Disease control rates for the two groups were 68.4%for the target and immunotherapy group and 52.3%for the target group.Notably,the median PFS for the target and immunotherapy group(5.8 months)exceeded that of the target group(4.5 months),with statistical significance(P=0.0135).AEs were comparable between the two groups,and only three patients(7.5%)experienced treatment-related third-grade AEs;importantly,there were no treatment-related fatalities.This study provides compelling evidence supporting the combination therapy of furquintinib and a PD-L1 inhibitor for mCRC patients.The data demonstrated that the combination therapy not only yielded improved survival benefits but also maintained manageable levels of toxic reactions when compared to furquintinib monotherapy.
作者
黄彬
俞甲子
金梁斌
彭涛
费正磊
HUANG Bin;YU Jia-zi;JIN Liang-bin;PENG Tao;FEI Zheng-lei(Health Science Center,Ningbo University,Ningbo 315211,China;Colon and Proctology Surgery,the Affiliated Lihuili Hospital,Ningbo University,Ningbo 315000,China)
出处
《药物生物技术》
CAS
2024年第2期153-159,共7页
Pharmaceutical Biotechnology
基金
2022浙江省卫生健康计划(No.2022KY1093)。
